Aditxt Introduces AditxtScore™ for COVID-19 and Announces the Completion of Validation Studies by Stanford Blood Center
Company Plans to file for an Emergency Use Authorization (EUA) and 510(k) Application in the Current Quarter (Q3, 2020)
Loma Linda, CA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditxt Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming, today introduced AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens, as validated in studies performed by Stanford Blood Center, headquartered in Palo Alto, California.
AditxtScore™ for COVID-19 is a double-multiplex assay that can be used to detect and differentiate various antibody isotypes (IgG, IgM, IgA) against multiple SARS-CoV-2 antigens (e.g. RBD, S1, NP) simultaneously in a single reaction. Currently, one of the most widely used platforms, ELISA, can only detect one antibody isotype against one antigen at a time. AditxtScore™ for COVID-19 increases the resolution of results obtained for each antibody isotype thereby enhancing sensitivity for monitoring changes in these values over time. Due to the enhanced specificity and sensitivity of this comprehensive antibody profiling system, false positive and false negative results have proven to be significantly reduced when testing for the antibodies produced to SARS-CoV-2, thereby expanding its utility beyond a tool used in epidemiology. Therefore, and importantly, AditxtScore™ for COVID-19 can serve as a valuable tool to evaluate immune responses to SARS-CoV-2 vaccines in clinical settings.
Aditxt plans to file for an Emergency Use Authorization (EUA) followed by a 510(K) application with the U.S. Food and Drug Administration by the end of the current quarter (Q3, 2020). Additionally, Aditxt is planning its operational capabilities in anticipation of beginning pilot programs utilizing AditxtScore™ for COVID-19 in Q4, 2020, with the goal of making AditxtScore™ commercially available starting in Q1, 2021.
Harpreet Sandhu, Chief Executive Officer of Stanford Blood Center (SBC), commented, “The AditxtScore™ for COVID-19 has the potential to be a game changer for our industry. AditxtScore™ for COVID-19 is a multiplexed platform that has shown tremendous speed and accuracy, which is extremely critical for meeting the ongoing COVID-19 challenge. My team and I look forward to further exploring this platform and potentially collaborating with Aditxt on future projects.”
Amro Albanna, Co-founder nd Chief Executive Officer of Aditxt, added, “Our vision for AditxtScore™ is to transform immune diagnosis from reactive testing to proactive monitoring. The AditxtScore™ platform is a transformative approach for monitoring and predicting immune responses by providing meaningful information in a timely manner. Now that we have successfully completed the validation study of the first product, our goal is to quickly secure the necessary regulatory requirements to deploy AditxtScore™ for COVID-19 and contribute to addressing the current national and global pandemic we are all facing. The AditxtScore™ platform is built to evaluate the status of the immune system and the COVID-19 application is only the first product to demonstrate its potential. We are actively working to develop AditxtScore™ for other applications, including predicting immune responses to vaccination and early detection of Type I Diabetes, among others.”
About Stanford Blood Center
About Aditxt Therapeutics
Smarter Strategies for IoT Deployment
IoT Evolution #TECHSUPERSHOW Grand Opening Reception on Expo Floor